Eupraxia Pharmaceuticals (TSX:EPRX) EPS (Basic): C$-1.44 (TTM As of Mar. 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
37 GF Score
Price C$8.89
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals EPS (Basic)?

Eupraxia Pharmaceuticals TSX:EPRX -2.84% 37 EPS (Basic) is C$-1.44 as of Mar. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Eupraxia Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$-0.32. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-1.44.

Eupraxia Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was C$-0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-1.44.

Eupraxia Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was C$-0.35. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.44.

During the past 3 years, the average EPS without NRI Growth Rate was -3.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -18.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Eupraxia Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 14.70% per year. The lowest was -68.80% per year. And the median was -12.55% per year.

Eupraxia Pharmaceuticals  (TSX:EPRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Eupraxia Pharmaceuticals EPS (Basic) Related Terms

Eupraxia Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals EPS (Basic) Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -1.89 -1.30 -1.57 -1.08 -1.42

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.36 -0.26 -0.51 -0.32
TSX:EPRX
37GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Eupraxia Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-53.216-0)/39.956
=-1.33

Eupraxia Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-17.36-0)/56.713
=-0.31

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of C$-1.44 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a EPS (Basic) of C$-1.44 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Eupraxia Pharmaceuticals and its competitors.
Is Eupraxia Pharmaceuticals' EPS (Basic) too high?
Eupraxia Pharmaceuticals' current EPS (Basic) is C$-1.44. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Eupraxia Pharmaceuticals' EPS (Basic) of C$-1.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current EPS (Basic) is C$-1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current EPS (Basic) of C$-1.44. The current EPS (Basic) is C$-1.44. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current EPS (Basic) is C$-1.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score

Get the complete analysis for TSX:EPRX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$8.89
Price